Glomerular Diseases
Publication Date: October 1, 2021
Last Updated: January 3, 2024
Chapter 2: Immunoglobulin A nephropathy (IgAN)/immunoglobulin A vasculitis (IgAV)
Recommendation 2.3.1
We recommend that all patients have their blood pressure managed, as described in Chapter 1. If the patient has proteinuria >0.5 g/d, we recommend that initial therapy be with either an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB). (Level 1, B)
312054
Chapter 3: Membranous nephropathy
Recommendation 3.3.1
For patients with MN and at least one risk factor for disease progression, we recommend using rituximab or cyclophosphamide and alternate month glucocorticoids for 6 months, or CNI-based therapy for ≥6 months, with the choice of treatment depending on the risk estimate. (Level 1, B)
312054
Overview
Title
Management of Glomerular Diseases
Authoring Organizations
Kidney Disease Improving Global Outcomes
National Kidney Foundation
To continue viewing this pocket guide, please purchase it.
My Library
added to your library.
Grading Table
Feedback